Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 37Carcinoma, Non-Small-Cell Lung 29Prostatic Neoplasms 20Neoplasm Metastasis 19Breast Neoplasms 19Colorectal Neoplasms 17Squamous Cell Carcinoma of Head and Neck 14Leukemia, Myeloid, Acute 14Stomach Neoplasms 12Ovarian Neoplasms 12Melanoma 12Lung Neoplasms 12Carcinoma, Hepatocellular 12Recurrence 11Hematologic Neoplasms 10Endometrial Neoplasms 10Rectal Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Pancreatic Neoplasms 9Lymphoma 9Head and Neck Neoplasms 9Myasthenia Gravis 8Leukemia 8Urinary Bladder Neoplasms 7Neoplasms by Site 7Neoplasms by Histologic Type 7Lymphoma, Large B-Cell, Diffuse 7Glioblastoma 7Fatigue 6Colonic Neoplasms 6

Interventions

relatlimab 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Muscle Invasive Bladder Urothelial Carcinoma × 1 year × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡